
Multiple sclerosis patients had fewer relapses with immediate treatment of clinically isolated disease but no improvement in disability outcomes, data from a randomized trial showed.
Patients who received immediate treatment with interferon had a 36% lower 10-year odds for progression to clinically definite MS and lower relapse rates at five and 10 years.
However, disability scores, MRI-visible lesions, and the rate of progressive disease at 10 years all did not differ between patients randomized ...